Security Snapshot

UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) Institutional Ownership

CUSIP: M96088105

13F Institutional Holders and Ownership History from Q2 2017 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

166

Shares (Excl. Options)

43,711,456

Price

$23.42

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Ordinary Shares, par value NIS 0.01 per share
Symbol
URGN on Nasdaq
Shares outstanding
46,986,408
Price per share
$17.98
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
43,711,456
Total reported value
$1,023,589,169
% of total 13F portfolios
0%
Share change
-54,779
Value change
+$14,661,993
Number of holders
166
Price from insider filings
$17.98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share is tracked under CUSIP M96088105.
  • 166 institutions reported positions in Q4 2025.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 166 to 8 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,023,589,169 to $29,854,160.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 166 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP M96088105?
CUSIP M96088105 identifies URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Paradigm Biocapital Advisors LP 9% +80% $84,110,876 +$37,586,159 4,216,084 +81% Paradigm BioCapital Advisors LP 30 Sep 2025
MORGAN STANLEY 5.4% +180% $35,433,378 +$24,712,637 2,488,299 +231% Morgan Stanley 30 Jun 2025
MENORA MIVTACHIM HOLDINGS LTD. 5% $24,780,614 2,303,031 Menora Mivtachim Holdings Ltd 11 Mar 2025
TORONTO DOMINION BANK 4.9% -29% $45,655,283 -$17,612,530 2,302,334 -28% The Toronto-Dominion Bank 31 Dec 2025
BlackRock, Inc. 5% $31,292,937 2,284,206 BlackRock, Inc. 30 Jun 2025
Soleus Capital Master Fund, L.P. 4.7% -6% $31,114,400 -$1,993,600 2,185,000 -6% Soleus Capital Master Fund, L.P. 30 Jun 2025
Adage Capital Management, L.P. 2.8% -60% $13,740,520 -$17,765,685 1,277,000 -56% Adage Capital Management, L.P. 31 Mar 2025
Monograph Capital Holdings Advisors, LLC 1.8% $8,503,556 838,615 Monograph Capital Partners I, L.P. 05 Jun 2025

As of 31 Dec 2025, 166 institutional investors reported holding 43,711,456 shares of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN). This represents 93% of the company’s total 46,986,408 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 9.7% 4,543,895 0% 1.1% $106,418,021
Paradigm Biocapital Advisors LP 9.5% 4,473,648 +6.1% 2.8% $104,772,836
BlackRock, Inc. 5.5% 2,601,009 +0.76% 0% $60,915,631
MORGAN STANLEY 5.5% 2,562,901 +1.4% 0% $60,023,155
Jefferies Financial Group Inc. 4.7% 2,199,652 0% 0.42% $51,515,850
SILVERARC CAPITAL MANAGEMENT, LLC 3.7% 1,738,821 +10% 5.9% $40,723,188
ACORN CAPITAL ADVISORS, LLC 3.1% 1,448,420 +15% 11% $33,921,996
SG Americas Securities, LLC 2.9% 1,377,647 +19% 0.04% $32,264,000
AMERICAN CENTURY COMPANIES INC 2.9% 1,358,812 0.02% $31,823,425
MENORA MIVTACHIM HOLDINGS LTD. 2.5% 1,152,531 0% 0.13% $26,992,276
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 2.4% 1,125,100 0.04% $26,349,842
D. E. Shaw & Co., Inc. 2% 962,624 +8.3% 0.02% $22,544,654
MPM BIOIMPACT LLC 2% 941,378 +597% 2.5% $22,047,073
ORBIMED ADVISORS LLC 1.9% 875,487 +27% 0.44% $20,503,906
STATE STREET CORP 1.7% 807,421 -1.5% 0% $18,909,800
FRONTIER CAPITAL MANAGEMENT CO LLC 1.7% 781,620 0.19% $18,305,546
Migdal Insurance & Financial Holdings Ltd. 1.6% 770,909 0% 0.16% $18,055,000
CITADEL ADVISORS LLC 1.6% 737,757 +22% 0.01% $17,278,269
SUPERSTRING CAPITAL MANAGEMENT LP 1.5% 718,354 +717% 9% $16,823,851
TCG Crossover Management, LLC 1.5% 717,347 0% 0.56% $16,800,267
MILLENNIUM MANAGEMENT LLC 1.3% 618,952 -58% 0.01% $14,495,856
PRICE T ROWE ASSOCIATES INC /MD/ 1.3% 616,606 +73% 0% $14,441,000
J. Goldman & Co LP 1.1% 513,303 0.47% $12,021,556
Woodline Partners LP 1.1% 500,726 +63% 0.05% $11,727,003
Boxer Capital Management, LLC 1.1% 500,000 -13% 2.6% $11,710,000

Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,660,412 $29,854,160 +$5,037,397 $17.98 8
2025 Q4 43,711,456 $1,023,589,169 +$14,661,993 $23.42 166
2025 Q3 43,904,765 $877,180,169 +$94,297,658 $19.95 159
2025 Q2 39,798,464 $545,161,051 +$3,475,596 $13.70 149
2025 Q1 41,643,932 $460,619,197 +$59,835,372 $11.06 139
2024 Q4 36,306,231 $386,611,717 -$9,614,830 $10.65 139
2024 Q3 35,097,143 $445,735,362 -$58,506,168 $12.70 127
2024 Q2 38,225,503 $641,423,803 +$207,327,873 $16.78 114
2024 Q1 27,162,024 $407,381,837 +$84,866,378 $15.00 111
2023 Q4 21,390,291 $320,854,510 +$51,912,609 $15.00 103
2023 Q3 17,724,118 $248,330,352 +$65,704,038 $14.01 100
2023 Q2 13,209,673 $136,728,106 +$7,180,182 $10.35 84
2023 Q1 12,428,895 $114,822,764 -$4,446,429 $9.24 64
2022 Q4 13,022,042 $115,449,037 -$2,381,858 $8.87 63
2022 Q3 13,319,758 $110,811,074 -$981,981 $8.32 56
2022 Q2 13,444,839 $109,243,080 -$6,040,297 $8.19 60
2022 Q1 14,223,995 $123,920,902 +$1,868,931 $8.71 82
2021 Q4 14,650,914 $139,360,752 +$2,176,410 $9.51 71
2021 Q3 14,085,432 $236,906,894 +$1,235,828 $16.82 88
2021 Q2 13,993,075 $213,691,867 -$5,527,357 $15.27 78
2021 Q1 14,299,652 $278,497,797 -$4,203,728 $19.48 88
2020 Q4 14,549,849 $261,548,580 -$10,506,654 $18.02 81
2020 Q3 15,009,007 $288,527,801 +$6,244,867 $19.29 78
2020 Q2 14,672,947 $381,998,824 +$28,263,022 $26.12 83
2020 Q1 13,991,634 $249,248,555 -$10,038,151 $17.84 78
2019 Q4 14,182,815 $472,998,729 +$4,841,998 $33.37 85
2019 Q3 14,565,725 $346,785,326 -$26,211,624 $23.83 83
2019 Q2 14,681,109 $527,197,234 +$43,911,794 $35.94 84
2019 Q1 13,462,231 $497,232,334 +$142,583,669 $36.94 73
2018 Q4 9,585,700 $412,953,000 +$18,631,256 $43.06 63
2018 Q3 9,922,967 $468,843,000 +$14,656,634 $47.23 70
2018 Q2 9,602,369 $482,439,000 +$24,129,548 $49.76 60
2018 Q1 9,137,601 $454,036,000 +$118,577,913 $49.69 43
2017 Q4 5,741,200 $213,691,000 +$83,149,343 $37.21 40
2017 Q3 3,121,706 $98,400,000 +$1,688,330 $31.52 29
2017 Q2 4,717,310 $85,197,000 +$85,197,000 $18.06 21